Mutual of America Capital Management LLC decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 86,095 shares of the life sciences company's stock after selling 5,110 shares during the period. Mutual of America Capital Management LLC owned approximately 0.05% of Illumina worth $11,228,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the stock. Janney Montgomery Scott LLC grew its stake in Illumina by 41.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company's stock valued at $422,000 after purchasing an additional 900 shares during the last quarter. Bleakley Financial Group LLC purchased a new stake in Illumina in the first quarter valued at approximately $207,000. Orion Portfolio Solutions LLC increased its holdings in Illumina by 10.4% in the 1st quarter. Orion Portfolio Solutions LLC now owns 7,918 shares of the life sciences company's stock worth $1,087,000 after buying an additional 746 shares during the period. Vanguard Group Inc. lifted its stake in Illumina by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company's stock valued at $2,505,409,000 after acquiring an additional 66,528 shares during the period. Finally, Edgestream Partners L.P. purchased a new stake in shares of Illumina in the 1st quarter valued at $384,000. Institutional investors and hedge funds own 89.42% of the company's stock.
Illumina Price Performance
ILMN stock traded down $4.31 during mid-day trading on Monday, reaching $130.74. The company's stock had a trading volume of 2,551,548 shares, compared to its average volume of 2,022,282. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The company's 50 day moving average is $139.66 and its two-hundred day moving average is $124.31. Illumina, Inc. has a fifty-two week low of $93.39 and a fifty-two week high of $156.66. The stock has a market cap of $20.74 billion, a PE ratio of -13.55 and a beta of 1.13.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 earnings per share. Equities research analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have weighed in on the company. Hsbc Global Res raised Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Daiwa America upgraded Illumina to a "strong-buy" rating in a research report on Friday, August 16th. Barclays upped their price objective on Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $164.00.
Read Our Latest Stock Analysis on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
